Taral Patel, MD
Interventional Cardiology · Scottsdale, AZNPI 1730111642
Payments from drug & device makers
Across 535 payments — averaging $704.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$108K
- Angiodynamics, Inc.$103K
- Boston Scientific$88K
- Abbott$43K
- Cardiovascular Systems Inc.$16K
- Teleflex LLC$9K
- plus $10K from 32 others
What the payments were for
- Consulting fees$59,78335%
- Speaking & faculty fees$74,28043%
- Travel & lodging$17,40610%
- Food & beverage$16,47610%
- Education$3,2002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $108,028 |
| Angiodynamics, Inc. | 27 | $103,285 |
| Boston Scientific | 133 | $87,838 |
| Abbott | 68 | $42,700 |
| Cardiovascular Systems Inc. | 24 | $15,860 |
| Teleflex LLC | 15 | $9,324 |
| Arrow International, Inc. | 2 | $2,015 |
| Abiomed | 11 | $1,151 |
| Shockwave Medical, Inc | 9 | $1,117 |
| Johnson & Johnson | 60 | $813 |
| Asahi Intecc USA, Inc. | 10 | $801 |
| Amgen | 29 | $561 |
| Novartis | 32 | $458 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $361 |
| Inari Medical, Inc. | 7 | $350 |
| E.r. Squibb & Sons, L.L.C. | 22 | $263 |
| Pfizer | 13 | $203 |
| EMD Serono, Inc. | 2 | $194 |
| Siemens Medical Solutions USA, Inc. | 2 | $194 |
| Penumbra, Inc. | 2 | $178 |
| Philips North America LLC | 3 | $172 |
| Amarin Pharma, Inc. | 8 | $140 |
| AstraZeneca | 7 | $129 |
| Astellas Pharma US Inc | 7 | $118 |
| EKOS Corporation | 2 | $101 |
| Pharmacosmos Therapeutics Inc. | 1 | $100 |
| Edwards Lifesciences | 1 | $88 |
| Asahi Intecc CO., LTD. | 1 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Acist Medical Systems, Inc. | 1 | $19 |
| CMP Pharma, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| B. Braun Interventional Systems Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Celonova Biosciences, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$24,570
- Xience V coronary stent system$24,440
- Coronary Orbital Atherectomy System$14,441
- CROSSBOSS$11,988
- AlphaVac$10,818
- GENERAL BALLOONS$7,500
- GENERAL - STRUCTURAL HEART$5,625
- GUIDELINER V3 CATHETER$5,415
- CATHETERS - ARROW$5,200
- Dragonfly OCT$4,919
- Emboshield NAV6 system$4,491
- AVVIGO Guidance System$3,402
- POLARIS$3,000
- GENERAL - THERAPIES$2,102
- AngioVac$1,781
- Diamondback Coronary$900
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$864
- Impella$819
- ASAHI PTCA Guide Wire$392
- COROFLOW$238
How this compares
$376,784 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 179 | $226,547 |
| XareltoRivaroxaban | 54 | $57,562 |
| EntrestoSacubitril/Valsartan | 21 | $30,839 |
| JardianceEmpagliflozin | 28 | $28,303 |
| Repatha SureclickEvolocumab | 33 | $26,081 |
| BrilintaTicagrelor | 27 | $25,556 |
| FarxigaDapagliflozin Propanediol | 11 | $6,753 |
| Metoprolol Succinate | 284 | $3,652 |
| ClopidogrelClopidogrel Bisulfate | 267 | $3,395 |
| Rosuvastatin Calcium | 233 | $3,138 |
| Atorvastatin Calcium | 337 | $3,125 |
| Flecainide Acetate | 28 | $1,909 |
| Losartan Potassium | 188 | $1,713 |
| Midodrine Hcl | 11 | $1,345 |
| Ezetimibe | 83 | $1,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $203 | $226,547179 claims |
| Johnson & JohnsonXarelto | $813 | $57,56254 claims |
| AstraZenecaBrilinta, Farxiga | $129 | $32,30938 claims |
| NovartisEntresto | $458 | $30,83921 claims |
| Boehringer IngelheimJardiance | $16 | $28,30328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Scottsdale
- Andrew CluckeyScottsdale$116K
- Rebecca ChesterScottsdale$113K
- Mayurkumar BhaktaScottsdale$82K
- Nassim HaddadScottsdale$53K
- Kwan LeeScottsdale$53K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
- Timothy ByrnePhoenix$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.